U.S. House of Representatives Overwhelmingly Approves FDA Legislation
Legislation will Expedite Approval of New Drugs and Therapies
Last night, by a vote of 387-5, the United States House of Representatives approved legislation that will expedite treatments for Parkinson's and other diseases.
As you may recall, every five years, Congress must reauthorize legislation – the Medical Device User Fee Act (MDUFA) and the Prescription Drug User Fee Act (PDUFA) – which enables the FDA to collect fees from the pharmaceutical and medical device industries to partially fund the agency's efforts to approve new drugs and therapies. During this process, Congress often simultaneously approves related legislation with significance to the Parkinson's community.
The legislation approved last night includes portions of the FAST Act, H.R. 4132, which is intended to streamline and hasten the FDA's therapy approval process and ensure people with diseases like Parkinson's have quicker access to safe and effective therapies.
Last week, the Senate voted on its own version of this legislation, including portions of the TREAT Act, S. 2113, which is similar to the FAST Act.
Now, the two versions of the bill will move to conference where members of both the House and Senate will iron out any differences before sending a unified version to the president for final passage into law. There is strong congressional desire to finalize this legislation by the end of June, and the legislation needs to be signed by the president by the end of September to keep the FDA functioning at its current levels.
Advancement of measures to expedite treatments for Parkinson's and other diseases is a testament to this community's advocacy efforts. We will update you as this legislation moves forward.